Phase II Study of Biweekly Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric Cancer

Publisher： Karger

E-ISSN： 1423-0232|77|1|49-52

ISSN： 0030-2414

Source： Oncology, Vol.77, Iss.1, 2009-06, pp. : 49-52

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I/II Study of a Combination of S-1 and Weekly Paclitaxel in Patients with Advanced or Recurrent Gastric Cancer

By  

Oncology, Vol. 72, Iss. 3-4, 2008-01 ,pp. : 219-225

Karger

Access to resources Recommend Favorite

Inflammation-Based Prognostic Score Predicts Survival in Patients with Advanced Gastric Cancer Receiving Biweekly Docetaxel and S-1 Combination Chemotherapy

By  

Oncology, Vol. 83, Iss. 4, 2012-08 ,pp. : 183-191

Karger

Access to resources Recommend Favorite

Phase I Study of a Combination of S-1 and Weekly Paclitaxel in Patients with Advanced or Recurrent Gastric Cancer

By  

Oncology, Vol. 69, Iss. 3, 2005-10 ,pp. : 261-268

Karger

Access to resources Recommend Favorite

Phase II Study of a Combination of Irinotecan and S-1 in Patients with Advanced Gastric Cancer (OGSG0002)

By  

Oncology, Vol. 73, Iss. 1-2, 2008-03 ,pp. : 65-71

Karger

Access to resources Recommend Favorite

Phase II Study of Docetaxel and Capecitabine in Patients with Metastatic or Recurrent Gastric Cancer

By  

Oncology, Vol. 68, Iss. 2-3, 2005-07 ,pp. : 190-195

Karger

Access to resources Recommend Favorite